By Erica Teichert ( May 9, 2014, 4:04 PM EDT) -- Teva Pharmaceutical Industries Ltd. urged a Washington, D.C., federal court on Thursday to bar the U.S. Food and Drug Administration from approving generic versions of its multiple sclerosis treatment Copaxone unless they meet more stringent clinical trial standards, claiming the cheaper alternatives might pose risks to consumers....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.